The success of CDK4/6 inhibitors in HR+/HER2− breast cancer has prompted further research into their potential in other cancer types and combinations with targeted therapies, chemotherapy, and immunotherapy [12]. The gene discussed is CDK4; the disease is breast carcinoma.